Lunsumio 유럽 연합 - 루마니아어 - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - limfom, folicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.